Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.

[1]  J. Knobloch,et al.  Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. , 2016, The Journal of antimicrobial chemotherapy.

[2]  A. Oliver,et al.  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. , 2016, The Journal of antimicrobial chemotherapy.

[3]  S. Karanika,et al.  Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Oliver,et al.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2016, Antimicrobial Agents and Chemotherapy.

[5]  B. Cao,et al.  Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013 , 2015, Antimicrobial Agents and Chemotherapy.

[6]  N. Mutters,et al.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  U. Theuretzbacher,et al.  Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  J. Turnidge,et al.  Reviving old antibiotics. , 2015, The Journal of antimicrobial chemotherapy.

[9]  R. Koerner,et al.  Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. , 2014, The Journal of antimicrobial chemotherapy.

[10]  J. Rodríguez-Baño,et al.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Timothy R. Walsh,et al.  Tackling antibiotic resistance , 2011, Nature Reviews Microbiology.

[12]  R. Yost,et al.  The Retrospective Cohort of Extended‐Infusion Piperacillin‐Tazobactam (RECEIPT) Study: A Multicenter Study , 2011, Pharmacotherapy.

[13]  D. Paterson,et al.  Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Livermore,et al.  Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. , 2011, International journal of antimicrobial agents.

[15]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  N. Wellinghausen,et al.  Evaluation of the Merlin MICRONAUT System for Rapid Direct Susceptibility Testing of Gram-Positive Cocci and Gram-Negative Bacilli from Positive Blood Cultures , 2007, Journal of Clinical Microbiology.

[17]  R. Andrade,et al.  Determinants of the clinical expression of amoxicillin‐clavulanate hepatotoxicity: A prospective series from Spain , 2006, Hepatology.

[18]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[19]  V. Jarlier,et al.  Comparative potency of mecillinam and other β-lactam antibiotics against Escherichia coli strains producing different β-lactamases , 2000 .

[20]  Anthony D. Harris,et al.  Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients , 2000, Antimicrobial Agents and Chemotherapy.